Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine

• Váldodahkkit: William R. Lykins (Dahkki), Jeroen Pollet (Dahkki), Jessica A. White (Dahkki), Brian Keegan (Dahkki), Leroy Versteeg (Dahkki), Ulrich Strych (Dahkki), Wen-Hsiang Chen (Dahkki), Raodoh Mohamath (Dahkki), Gabi Ramer-Denisoff (Dahkki), Sierra Reed (Dahkki), Samuel Beaver (Dahkki), Alana Gerhardt (Dahkki), Emily A. Voigt (Dahkki), Mark A. Tomai (Dahkki), Robert Sitrin (Dahkki), Robert K. M. Choy (Dahkki), Frederick J. Cassels (Dahkki), Peter J. Hotez (Dahkki), Maria Elena Bottazzi (Dahkki), Christopher B. Fox (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2024-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction: Since their introduction, adjuvanted recombinant subunit vaccines against COVID-19 have played a pivotal role in protecting global populations. Optimizing the immune response's quality, amplitude, and durability to these vaccines depends on the appropriate adjuvant choice and dose...